ARTEMIS – IGaN is a maximum 160 week a Phase 3 trial evaluating the Safety and Efficacy of OMS721 in patients with Immunoglobulin A (IgA) Nephropathy
- Biopsy confirmed diagnosis of IgAN (may be provided)
- Kidney or any other soild organ transplant recipient or planned transplat during the study
- Body mass index ≥ 35 kg/m²
The study consists of five periods: Screening, Run-In, Initial Treatment (Weeks 1-12)
Response Evaluation (Weeks 13-24)
Follow-Up (Weeks 25 to end-of-study)
The study duration for each patient is expected to last up to 160 weeks.